# Roberto Salgado

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 88 papers | 16,224 citations | 57758 44 h-index | 53230 85 g-index |
| 90 all docs | 90 docs citations | 90 times ranked | 17864 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 147-162. | 2.8 | 9 |
| 2 | Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3. | 5.2 | 33 |
| 3 | Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374. | 1.6 | 45 |
| 4 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European Journal of Cancer, 2022, 166, 219-228. | 2.8 | 12 |
| 5 | Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively. European Journal of Cancer, 2022, 168, 138-140. | 2.8 | 2 |
| 6 | What's in a name? That which we call Immune Cells by any other name would all smell as sweet. Clinical Cancer Research, 2022, , . | 7.0 | 0 |
| 7 | Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. Npj Breast Cancer, 2022, 8, 56. | 5.2 | 3 |
| 8 | Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369. | 5.5 | 18 |
| 9 | Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086. , 2021, , . | | 9 |
| 10 | National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020. JCO Oncology Practice, 2021, 17, e1763-e1773. | 2.9 | 11 |
| 11 | Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. Npj Breast Cancer, 2021, 7, 67. | 5.2 | 8 |
| 12 | Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. Npj Breast Cancer, 2021, 7, 86. | 5.2 | 9 |
| 13 | What do we still need to learn on digitally assessed biomarkers?. EBioMedicine, 2021, 70, 103520. | 6.1 | 8 |
| 14 | Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective. Annals of Oncology, 2021, 32, 1316-1321. | 1.2 | 4 |
| 15 | Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature Communications, 2021, 12, 5668. | 12.8 | 91 |
| 16 | Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. Breast Cancer Research and Treatment, 2021, 189, 599-606. | 2.5 | 11 |
| 17 | Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 2021, 597, 555-560. | 27.8 | 36 |
| 18 | Genomic-adjusted radiation dose to personalise radiotherapy. Lancet Oncology, The, 2021, 22, 1200-1201. | 10.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Annals of Oncology, 2021, 32, 1236-1244. | 1.2 | 109 |
| 20 | Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. Breast, 2021, 59, 183-192. | 2.2 | 10 |
| 21 | Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636. | 1.2 | 86 |
| 22 | Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass ), 2021, 27, 25-31. | 2.0 | 12 |
| 23 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819. | 6.3 | 319 |
| 24 | Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. Nature Communications, 2021, 12, 6201. | 12.8 | 57 |
| 25 | Quantity of Immune Cells Predict Response to Immunotherapy in Cancer. EClinicalMedicine, 2021, 41, 101170. | 7.1 | 2 |
| 26 | Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11. | 16.8 | 126 |
| 27 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150. | 5.2 | 112 |
| 28 | A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study. Journal of Pathology Informatics, 2021, 12, 45. | 1.7 | 17 |
| 29 | Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncology, The, 2020, 21, 1283-1295. | 10.7 | 213 |
| 30 | How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncology, The, 2020, 21, 1399-1401. | 10.7 | 34 |
| 31 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research, 2020, 26, 5668-5681. | 7.0 | 37 |
| 32 | Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335. | 12.8 | 46 |
| 33 | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15. | 5.2 | 16 |
| 34 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16. | 5.2 | 90 |
| 35 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17. | 5.2 | 106 |
| 36 | Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nature Medicine, 2020, 26, 1054-1062. | 30.7 | 181 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The path to a better biomarker: application of a risk management framework for the implementation of PDâ€L1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684. | 4.5 | 142 |
| 38 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology, 2020, 31, 569-581. | 1.2 | 253 |
| 39 | The 2019 World Health Organization classification of tumours of the breast. Histopathology, 2020, 77, 181-185. | 2.9 | 395 |
| 40 | Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2020, 80, PD5-03-PD5-03. | 0.9 | 34 |
| 41 | The Future of Pathology: What can we Learn from the COVID-19 Pandemic?. Journal of Pathology Informatics, 2020, 11, 15. | 1.7 | 15 |
| 42 | Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136. | 2.8 | 8 |
| 43 | Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine, 2019, 25, 920-928. | 30.7 | 589 |
| 44 | Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485. | 27.8 | 639 |
| 45 | Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 867-871. | 6.3 | 41 |
| 46 | Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569. | 1.6 | 505 |
| 47 | Tumor Banks: A Quality Control Scheme Proposal. Frontiers in Medicine, 2019, 6, 225. | 2.6 | 7 |
| 48 | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research, 2019, 21, 151. | 5.0 | 30 |
| 49 | Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Annals of Oncology, 2019, 30, 1941-1949. | 1.2 | 155 |
| 50 | Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology, 2019, 30, 236-242. | 1.2 | 123 |
| 51 | Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Journal of Clinical Investigation, 2019, 129, 1785-1800. | 8.2 | 266 |
| 52 | Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. Journal of Clinical Oncology, 2019, 37, 1012-1012. | 1.6 | 35 |
| 53 | Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776. | 6.3 | 76 |
| 54 | Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150. | 9.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. Seminars in Cancer Biology, 2018, 52, 158-165. | 9.6 | 4 |
| 56 | Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€"Positive/Human Epidermal Growth Factor Receptor 2â€"Negative Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 2804-2811. | 7.0 | 249 |
| 57 | Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, 16-25. | 9.6 | 303 |
| 58 | Steps forward for cancer precision medicine. Nature Reviews Drug Discovery, 2018, 17, 1-2. | 46.4 | 37 |
| 59 | Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncology, The, 2018, 19, 3-5. | 10.7 | 30 |
| 60 | Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars in Cancer Biology, 2018, 52, 151-157. | 9.6 | 108 |
| 61 | In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. Seminars in Cancer Biology, 2018, 52, v-vi. | 9.6 | 1 |
| 62 | Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993. | 30.7 | 689 |
| 63 | Transcriptomic and genomic features of invasive lobular breast cancer. Seminars in Cancer Biology, 2017, 44, 98-105. | 9.6 | 34 |
| 64 | Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2017, 57, 8-15. | 7.7 | 75 |
| 65 | Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology, The, 2017, 18, 52-62. | 10.7 | 225 |
| 66 | The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals of Oncology, 2017, 28, 321-328. | 1.2 | 72 |
| 67 | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606. | 12.8 | 89 |
| 68 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251. | 4.3 | 469 |
| 69 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021. | 10.7 | 716 |
| 70 | Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Annals of Oncology, 2017, 28, v608. | 1.2 | 117 |
| 71 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164. | 5.5 | 230 |
| 72 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097. | 4.5 | 82 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250. | 2.2 | 194 |
| 74 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582. | 12.8 | 412 |
| 75 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910. | 12.8 | 119 |
| 76 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241. | 27.6 | 679 |
| 77 | Evolving paradigms in multifocal breast cancer. Seminars in Cancer Biology, 2015, 31, 111-118. | 9.6 | 34 |
| 78 | An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786. | 5.5 | 195 |
| 79 | Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology, 2015, 1, 448. | 7.1 | 482 |
| 80 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271. | 1.2 | 2,122 |
| 81 | Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform.. Journal of Clinical Oncology, 2015, 33, 575-575. | 1.6 | 4 |
| 82 | Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316. | 1.8 | 14 |
| 83 | A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncology, The, 2014, 15, e184-e193. | 10.7 | 30 |
| 84 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of Oncology, 2014, 25, 1544-1550. | 1.2 | 1,022 |
| 85 | Evaluation of PI3K-pathwayâ€“activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status.. Journal of Clinical Oncology, 2014, 32, 11060-11060. | 1.6 | 0 |
| 86 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 2013, 31, 860-867. | 1.6 | 1,342 |
| 87 | CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892. | 8.2 | 813 |
| 88 | Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.. Journal of Clinical Oncology, 2013, 31, 11003-11003. | 1.6 | 0 |